Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost and balance sheet actions while outlining expectations for a return to growth in 2026 during the company's fourth-quarter and full-year 2025 earnings call. Management points to refinancing, manufacturing consolidation, and governance changes President and CEO John Duke said 2025 represented a "pivotal year
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | John D. Duke CEO | XMUN Exchange | US4169062043 ISIN |
| US Country | 339 Employees | - Last Dividend | 16 Mar 2026 Last Split | 7 Dec 2000 IPO Date |
Harvard Bioscience, Inc. is a premier developer, manufacturer, and seller of life science applications and technologies, reaching a global audience. With a foundation that dates back to 1901, the company has established itself as a leader in the life science community, catering to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. Harvard Bioscience also extends its offerings to contract research organizations and academic labs. Its product portfolio spans a wide range of cellular and molecular technology products designed to advance scientific research and drug development. Headquartered in Holliston, Massachusetts, the company is committed to innovation in life science research, emphasizing quality and precision in its products and services.
Designed for precision liquid handling, these pumps are essential for dosing and infusion applications in laboratory settings.
Used for cell manipulation techniques, these instruments facilitate the introduction of substances into cells or the fusion of cells, playing a critical role in genetic and cellular research.
Key in analyzing biological specimens, these devices support the detection and quantification of substances, aiding in complex molecular research.
Includes data acquisition systems for cellular analysis, micro electrode array solutions for in vivo and in vitro recordings, underpinning a broad spectrum of physiological and biological research.
Offer a platform to assess vital physiological data from organisms, supporting research, drug discovery, and drug development through telemetry systems, behavior products, and surgical instruments for lab research.
Comprehensive respiratory analysis systems, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation tools, crucial for respiratory research.
Provide a controlled environment for the study of respiratory health, pollutants, and therapeutics, facilitating inhalation research and drug efficacy studies.
These systems offer robust data gathering and analysis capabilities adhering to Good Laboratory Practice standards, essential for high-quality research output.
Harvard Bioscience markets its innovative products through a combination of sales organizations, websites, and distributors. The brand portfolio includes recognized names such as Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab, underscoring its commitment to quality and scientific advancement.